Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.50 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767756 | 0.85 | MEN1 (1.00) | KMT2ANPC1RAB9AMEN1FGFR1 | |
| SCHEMBL22509831 | 0.85 | KMT2A (0.71) | KMT2ANPC1RAB9AMEN1FGFR1 | |
| SCHEMBL27590143 | 0.85 | KMT2A (0.56) | KMT2ANPC1RAB9AMEN1FGFR1 | |
| SCHEMBL807074 | 0.83 | FGFR1 (0.57) | KMT2ANPC1RAB9AMEN1FGFR1 | |
| SCHEMBL22509832 | 0.83 | MEN1 (0.58) | KMT2ANPC1RAB9AMEN1FGFR1 | |
| Hydrochloric Acid SCHEMBL789680 | 0.82 | FGFR1 (0.55) | KMT2ANPC1RAB9AMEN1FGFR1 | |
| SCHEMBL28156921 | 0.80 | FGFR1 (0.62) | KMT2ANPC1RAB9AMEN1FGFR1 | |
| SCHEMBL790060 | 0.80 | FGFR1 (0.54) | KMT2ANPC1RAB9AMEN1FGFR1 | |
| SCHEMBL28280373 | 0.78 | FGFR1 (0.55) | KMT2ANPC1RAB9AMEN1FGFR1 | |
| SCHEMBL29374375 | 0.78 | PSMB5 (0.65) | KMT2ANPC1RAB9AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101171009-A | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3- receptor ligands | BIOPROJET SOC CIV (FR) | 2008-04-30 | — | — | CN | claimed |
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| CN-102812045-B | Materials and methods for treating or preventing human epidermal growth factor receptor-3 (HER-3) related diseases | 第三共欧洲有限公司 | 2018-04-13 | — | — | CN | disclosed |
| CN-103772373-B | As the quinazoline analogs of receptor tyrosine kinase inhibitors | 阿雷生物药品公司 | 2017-06-09 | — | — | CN | disclosed |
| CN-106432206-A | Method for synthesizing lapatinib or intermediate 5-(4-hydroxy quinazoline)-furan-2-formaldehyde of lapatinib | 成都美睿科生物科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106432205-A | Method for synthesizing lapatinib or intermediate thereof | 成都美睿科生物科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-103228632-B | Compounds as modulators of mutant CFTR proteins and their use in treating diseases associated with CFTR protein malfunction | 波兰科学院生物化学与生物物理研究所 | 2016-08-31 | — | — | CN | disclosed |
| CN-104496840-A | Compounds As Modulators Of A Mutant Cftr Protein And Their Use For Treating Diseases Associated With Cftr Protein Malfunction | INST BIOCHEMII I BIOFIZYKI PAN | 2015-04-08 | — | — | CN | disclosed |
| US-20140203270-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL HAVING SILICON-CONTAINING FOUR MEMBERED RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT ELEMENT | NIPPON STEEL & SUMIKIN CHEMICAL CO., LTD. (JP) | 2014-07-24 | — | — | US | disclosed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| CN-103228632-A | Compounds as modulators of mutant CFTR proteins and their use in treating diseases associated with CFTR protein malfunction | INST BIOCHEMII I BIOFIZYKI PAN | 2013-07-31 | — | — | CN | disclosed |
| CN-101171009-B | Use of non-imidazole alkylamines histamine h3- receptor ligands in treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia | BIOPROJET SOC CIV | 2012-11-07 | — | — | CN | disclosed |
| US-8288410-B2 | 3-substituted quinolinium and 7H-indolo[2,3-c]quinolinium salts as new antiinfectives | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120165369-A1 | 3-SUBSTITUTED QUINOLINIUM AND 7H-INDOLO[2,3-c]QUINOLINIUM SALTS AS NEW ANTIINFECTIVES | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY | 2012-06-28 | — | — | US | disclosed |
| CN-101605543-A | Compounds having activity in correcting mutant-CFTR processing and uses thereof | UNIV CALIFORNIA (US) | 2009-12-16 | — | — | CN | disclosed |
| CN-101605543-A | Compounds having activity in correcting mutant-CFTR processing and uses thereof | UNIV CALIFORNIA (US) | 2009-12-16 | — | — | CN | disclosed |
| CN-101171009-A | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3- receptor ligands | BIOPROJET SOC CIV (FR) | 2008-04-30 | — | — | CN | disclosed |
| WO-1998000750-A1 | PROCESS FOR PRODUCING LIQUID CRYSTAL ALIGNMENT LAYER AND LIQUID CRYSTAL DISPLAY DEVICE WITH THE USE OF THE SAME | HOECHST RESEARCH & TECHNOLOGY DEUTSCHLAND GMBH & CO. KG (DE) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165369-A1 | 3-SUBSTITUTED QUINOLINIUM AND 7H-INDOLO[2,3-c]QUINOLINIUM SALTS AS NEW ANTIINFECTIVES | IDO1, IDO2, NQO2 | KMT2A 2440/4885NPC1 3157/4885RAB9A 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.